Would repeat MMR/HER-2 or NGS testing be beneficial during progression of gastric cancer in patients who have already received first line chemotherapy?   

Patients with gastric cancer can acquire new targetable mutations on progression. This could aid in additional treatment options in this group which tend to have poorer outcomes.



Answer from: Medical Oncologist at Academic Institution